Tonix Pharmaceuticals has received FDA approval for its treatment, Tonmya, targeting fibromyalgia in adults. Availability is expected by Q4 2025. The approval follows successful Phase 3 trials showing significant pain reduction and good tolerability.
Analyst predictions vary, with TipRanks’ AI Analyst Spark assigning a Neutral rating to TNXP stock, citing mixed factors such as strong technical indicators but financial challenges. Tonix Pharma’s primary product, Tonmya, is designed for fibromyalgia treatment.
Key metrics include an average trading volume of 1,292,466 and a current market cap of $522.3M.
Source: https://www.tipranks.com/news/company-announcements/tonix-pharma-gains-fda-approval-for-tonmya